Fifth Third Wealth Advisors LLC Raises Stock Position in Boston Scientific Corporation $BSX

Key Points

• Fifth Third Wealth Advisors LLC increased its stake in Boston Scientific Corporation by 37.0% during the second quarter, owning 51,133 shares valued at $5,492,000.
• Multiple analysts have recently upgraded Boston Scientific's stock ratings, with price targets ranging from $124.00 to $128.00 and a general consensus rating of "Buy."
• Insider trading activity shows a notable sell-off, with Director Edward J. Ludwig selling 4,000 shares, indicating a 17.79% decrease in their ownership.

Fifth Third Wealth Advisors LLC lifted its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 37.0% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 51,133 shares of the medical equipment provider's stock after purchasing an additional 13,818 shares during the period. Fifth Third Wealth Advisors LLC's holdings in Boston Scientific were worth $5,492,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also modified their holdings of BSX. Sound Income Strategies LLC grew its holdings in Boston Scientific by 90.9% in the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider's stock valued at $27,000 after buying an additional 120 shares in the last quarter. 1248 Management LLC purchased a new stake in shares of Boston Scientific in the first quarter valued at about $26,000. Y.D. More Investments Ltd purchased a new stake in shares of Boston Scientific in the 1st quarter valued at approximately $27,000. Oliver Lagore Vanvalin Investment Group purchased a new stake in shares of Boston Scientific in the 2nd quarter valued at approximately $37,000. Finally, Activest Wealth Management grew its stake in shares of Boston Scientific by 6,216.7% in the 1st quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider's stock valued at $38,000 after buying an additional 373 shares during the period. Hedge funds and other institutional investors own 89.07% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Raymond James Financial increased their price objective on Boston Scientific from $121.00 to $124.00 and gave the stock a "strong-buy" rating in a research report on Thursday, July 24th. Weiss Ratings reiterated a "buy (b-)" rating on shares of Boston Scientific in a report on Wednesday. Robert W. Baird increased their price target on Boston Scientific from $123.00 to $128.00 and gave the stock an "outperform" rating in a report on Wednesday, October 1st. Oppenheimer upgraded Boston Scientific from a "market perform" rating to an "outperform" rating and increased their price target for the stock from $118.00 to $125.00 in a report on Monday, September 8th. Finally, Erste Group Bank lowered shares of Boston Scientific from a "buy" rating to a "hold" rating in a research note on Friday, October 3rd. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, Boston Scientific has an average rating of "Buy" and an average target price of $120.71.

Insider Buying and Selling

In related news, Director Edward J. Ludwig sold 4,000 shares of Boston Scientific stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the transaction, the director owned 18,479 shares in the company, valued at $1,959,328.37. The trade was a 17.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Yoshiaki Fujimori sold 2,901 shares of Boston Scientific stock in a transaction on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total transaction of $310,377.99. Following the sale, the director directly owned 2,081 shares of the company's stock, valued at approximately $222,646.19. This trade represents a 58.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 174,214 shares of company stock worth $17,972,457. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Stock Performance

Shares of BSX stock opened at $95.41 on Friday. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a 52 week low of $80.64 and a 52 week high of $109.50. The stock has a market capitalization of $141.38 billion, a PE ratio of 56.79, a P/E/G ratio of 2.34 and a beta of 0.61. The firm has a 50 day moving average of $101.98 and a two-hundred day moving average of $101.87.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. The firm had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.Boston Scientific's revenue was up 22.8% compared to the same quarter last year. During the same period last year, the business posted $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, research analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.